Almonty's Sangdong Output Meets a 69% Tungsten Slide and Two Lower Targets
Published on 10/29/2026 at 08:21 | Editorial boerse-global.deTwo brokers have trimmed their price targets on Almonty within days of each other, and neither cut came with a downgrade. That pairing — a lower number attached to a still-positive rating — is the thread running through the stock right now, and it sits alongside a commodity backdrop that has turned considerably less friendly.
Start with the metal. Chinese prices for ammonium paratungstate (APT), the tungsten intermediate, stood at 470,000 yuan per tonne on October 15, according to media reports. Measured against the mid-March high, that marks a decline of roughly 69%, part of what the report described as a broad correction across tungsten prices. This is an industry indicator, distinct from Almonty's own revenue and earnings trajectory — but it reframes the debate over the company's Sangdong mine, because operational milestones and a supportive price environment are not the same thing.
Two Cuts, One Direction, Different Reasons
Oppenheimer analyst Ian Zaffino lowered his target to US$19 from US$25 on October 15, citing lower valuation multiples among comparable companies. He kept his Outperform rating. The stated rationale points squarely at the valuation framework, so the adjustment should not be read as a verdict on production progress. Operational standing and the price analysts are willing to pay for it deserve to be weighed separately.
B. Riley Securities analyst Nick Giles moved the same day, cutting his target to US$20 from US$25 while reaffirming his Buy recommendation. Both houses pulled back their targets without abandoning their positive calls — a shared direction, though not necessarily a shared rationale. Oppenheimer's reference to lower peer multiples cannot simply be projected onto B. Riley's decision.
Should investors sell immediately? Or is it worth buying Almonty?
There is no contradiction in a Buy rating sitting beside a reduced target. The direction of the revision matters at least as much as the unchanged label: the recommendation held, while the expected achievable share value came down.
Sangdong's Timeline Becomes a Valuation Input
The operational clock provides part of the explanation. At an investor day just over a week ago, Almonty updated its expectations for deliveries from the two Sangdong expansion stages. Analysts responded by pushing their delivery assumptions further out and lowering their targets — turning the timing of shipments into a concrete valuation factor rather than a background detail.
Production itself has moved forward. A Monday media report noted that Almonty's Sangdong mine in Yeongwol has been producing industrial tungsten concentrate since September. That detail served as background to a report about a possible additional Korean stock exchange listing; it was not a fresh production announcement. The potential listing, via Korean depositary receipts, was described as the subject of talks with contacts in the securities industry — no confirmed corporate decision was attached to it.
Almonty at a turning point? This analysis reveals what investors need to know now.
Reading the Day's Move
Tuesday's 5.1% decline fits the more cautious picture, but it substantiates neither an additional operational setback nor a direct link to any single analyst decision. A single session's drop and a single shipment headline are each too narrow a lens.
The more useful question is what an unchanged Buy rating is worth when price assumptions and delivery expectations are both turning more conservative. It remains a positive assessment — not an all-clear. Production progress, listing ambitions and valuation assumptions are separate factors, and anyone drawing an investment conclusion from them should neither equate operational development with a fixed valuation nor treat a contemplated listing as a settled step.
Ad
Almonty Stock: New Analysis - 29 October
Fresh Almonty information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
